<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009629</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00142822</org_study_id>
    <secondary_id>R21AG061548</secondary_id>
    <nct_id>NCT04009629</nct_id>
  </id_info>
  <brief_title>Dementia Risk and Dynamic Response to Exercise</brief_title>
  <acronym>DYNAMIC</acronym>
  <official_title>Dementia Risk and Dynamic Response to Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research suggests that physical exercise supports brain health and cognition as we age. The&#xD;
      goal of this project is to examine the specific changes in brain blood flow and biological&#xD;
      factors in the blood immediately after exercise in older adults who have the APOE4 gene, a&#xD;
      genetic risk factor for developing Alzheimer's. Results from this study will help researchers&#xD;
      and clinicians understand and measure changes in the body and brain as a function of&#xD;
      exercise, and how those changes relate to Alzheimer's risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The brain and cardiovascular system share common risk factors for age-related diseases such&#xD;
      as hypertension, hypercholesterolemia, and genetics (e.g. APOE4). Because of this link, much&#xD;
      work has focused on the role of cerebrovascular health in reducing dementia risk. Regular&#xD;
      aerobic exercise has well-established benefits for cardiovascular health and has been&#xD;
      repeatedly linked to better cognition, brain health, and lower risk of Alzheimer's disease&#xD;
      (AD). Despite strong evidence for sustained cognitive and brain outcomes, the mechanisms&#xD;
      relating aerobic exercise with brain health and cognition remain imprecisely defined. Amongst&#xD;
      many potential mechanisms, cerebral blood flow (CBF) and blood-based biomarkers, such as&#xD;
      neurotrophins, are promising targets for their shared association to brain and cardiovascular&#xD;
      health. Prior investigations have largely attempted to measure change in these mechanisms&#xD;
      under resting conditions after an extended exercise intervention with mixed and conflicting&#xD;
      results. Further, studies have often not accounted for genetic differences that may blunt the&#xD;
      effect of exercise. Unlike prior work, our innovative approach is to begin by characterizing&#xD;
      the dynamic changes that result from an acute exercise challenge. A single bout of aerobic&#xD;
      exercise temporarily increases CBF and prompts neurotrophin release. These transient changes&#xD;
      ultimately drive long-term physiologic adaptation to exercise. Therefore, the study team will&#xD;
      characterize the dynamic response to an acute, standardized bout of aerobic exercise in a&#xD;
      group of nondemented older adults, comparing those who do and do not carry the APOE4 allele.&#xD;
      The first aim will test if CBF response to an acute exercise challenge is blunted in APOE4&#xD;
      carriers. The second aim will similarly test the acute exercise response of blood-based&#xD;
      biomarkers such as brain derived neurotrophic factor, insulin-like growth factor, and&#xD;
      vascular endothelial growth factor in APOE4 carriers versus non-carriers. The study team&#xD;
      expects that more accurately understanding the acute effects will provide valuable insight&#xD;
      into how aerobic exercise supports cognitive function and brain health. Armed with this&#xD;
      knowledge the field can optimize biomarker measurement for future exercise intervention&#xD;
      randomized controlled trials, informing our long-term goal of identifying precision exercise&#xD;
      prescription for AD prevention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2019</start_date>
  <completion_date type="Actual">October 28, 2021</completion_date>
  <primary_completion_date type="Actual">October 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single visit, case-control study identified as an intervention due to the use of a single bout of aerobic exercise under NIH rules (grants.nih.gov/policy/clinical-trials/definition.htm)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral Blood Flow Area Under Curve</measure>
    <time_frame>~24 minutes</time_frame>
    <description>Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin-like Growth Factor-1 Change</measure>
    <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
    <description>Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Growth Factor Change</measure>
    <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
    <description>Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Derived Neurotrophic Factor Change</measure>
    <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
    <description>Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Alzheimer Disease 2 Due to Apoe4 Isoform</condition>
  <condition>Healthy Aging</condition>
  <arm_group>
    <arm_group_label>Exercise - apolipoprotein e4 carrier</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 15 minute bout of moderate intensity aerobic exercise for individuals with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise - apolipoprotein e4 non-carrier</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 15 minute bout of moderate intensity aerobic exercise for individuals with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate Intensity Aerobic Exercise</intervention_name>
    <description>Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.</description>
    <arm_group_label>Exercise - apolipoprotein e4 carrier</arm_group_label>
    <arm_group_label>Exercise - apolipoprotein e4 non-carrier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 65-85&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Normal or corrected hearing or vision,&#xD;
&#xD;
          -  Without activity restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cognitive or psychiatric illness,&#xD;
&#xD;
          -  Anti- coagulant use,&#xD;
&#xD;
          -  High cardiovascular risk without physician clearance for exercise,&#xD;
&#xD;
          -  Exercise-limiting musculoskeletal condition,&#xD;
&#xD;
          -  MRI contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric D Vidoni, PT, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Alzheimer's Disease Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <results_first_submitted>February 9, 2022</results_first_submitted>
  <results_first_submitted_qc>May 2, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2022</results_first_posted>
  <last_update_submitted>May 2, 2022</last_update_submitted>
  <last_update_submitted_qc>May 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data may be shared with unaffiliated investigators after completion of data collection and a reasonable amount of analysis and dissemination time. Contact the PI for further information.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Following a reasonable amount of analysis and dissemination time, the data will be available via request.</ipd_time_frame>
    <ipd_access_criteria>Following institutional limits and recommendations and subject to use agreements.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT04009629/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>APOE4 Carrier</title>
          <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
        <group group_id="P2">
          <title>APOE4 Non-carrier</title>
          <description>Participants with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>APOE4 Carriers</title>
          <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
        <group group_id="B2">
          <title>APOE4 Non-carriers</title>
          <description>Participants with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" spread="5.1"/>
                    <measurement group_id="B2" value="73.3" spread="5.2"/>
                    <measurement group_id="B3" value="72.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Blood Flow Area Under Curve</title>
        <description>Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue</description>
        <time_frame>~24 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APOE4 Carrier</title>
            <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
          <group group_id="O2">
            <title>APOE4 Non-carrier</title>
            <description>Participants with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Blood Flow Area Under Curve</title>
          <description>Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue</description>
          <units>mL/100g tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="715" spread="105.0"/>
                    <measurement group_id="O2" value="751" spread="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin-like Growth Factor-1 Change</title>
        <description>Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise</description>
        <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
        <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>APOE4 Carrier</title>
            <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
          <group group_id="O2">
            <title>APOE4 Non-carrier</title>
            <description>Participants with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor-1 Change</title>
          <description>Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise</description>
          <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="22.8"/>
                    <measurement group_id="O2" value="5.7" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Endothelial Growth Factor Change</title>
        <description>Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise</description>
        <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
        <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>APOE4 Carrier</title>
            <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
          <group group_id="O2">
            <title>APOE4 Non-carrier</title>
            <description>Participants having zero copies of the APOE4 allele, the strongest late-onset genetic risk factor for Alzheimer's dementia.</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Endothelial Growth Factor Change</title>
          <description>Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise</description>
          <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="10.6"/>
                    <measurement group_id="O2" value="1.83" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Derived Neurotrophic Factor Change</title>
        <description>Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise</description>
        <time_frame>Pre-to-post intervention (~15 minutes)</time_frame>
        <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>APOE4 Carrier</title>
            <description>Participants with 1 or 2 copies of the ApoE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
          </group>
          <group group_id="O2">
            <title>APOE4 Non-carrier</title>
            <description>Participants having zero copies of the ApoE4 allele, the strongest late-onset genetic risk factor for Alzheimer's dementia.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Derived Neurotrophic Factor Change</title>
          <description>Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise</description>
          <population>Blood collection failed on three individuals in the APOE4 carrier group. Outcome could not be analyzed.</population>
          <units>picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-219" spread="641"/>
                    <measurement group_id="O2" value="208" spread="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <desc>Adverse events were defined as any untoward or unfavorable medical occurrence in a human subject participant, including any abnormal sign, symptom, or disease, temporally associated with the participants' involvement in the research, whether or not considered related to participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>APOE4 Carrier</title>
          <description>Participants with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
        <group group_id="E2">
          <title>APOE4 Non-carrier</title>
          <description>Participants with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Vidoni</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-0555</phone>
      <email>kuamp@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

